# Insight Molecular Diagnostics Inc.: overview

IMDX · Nasdaq · CIK 1642380 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/imdx.md) · [Financials](/companies/imdx/financials.md) · [Filings](/companies/imdx/filings.md) · [Insiders](/companies/imdx/insiders.md)

Latest reported revenue: [$239.0k](/filings/0001642380-26-000011.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 10, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001642380-26-000011).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.1](/filings/0001193125-25-274266.md) | [1.5 d](/filings/0001642380-26-000004.md) | [2.1](/filings/0001642380-26-000008.md) | [0.5](/filings/0001642380-26-000011.md) | [0.3](/filings/0001193125-25-274266.md) | [1.1 d](/filings/0001642380-26-000004.md) | [0.0](/filings/0001642380-26-000008.md) | [0.2](/filings/0001642380-26-000011.md) |
| Gross margin | % | [43.5%](/filings/0001193125-25-274266.md) | [40.0% d](/filings/0001642380-26-000004.md) | [62.0%](/filings/0001642380-26-000008.md) | [65.3%](/filings/0001642380-26-000011.md) | [53.5%](/filings/0001193125-25-274266.md) | [43.5% d](/filings/0001642380-26-000004.md) | [46.9%](/filings/0001642380-26-000008.md) | [65.7%](/filings/0001642380-26-000011.md) |
| Operating margin | % | [(11752.2%)](/filings/0001193125-25-274266.md) | [(2262.9%) d](/filings/0001642380-26-000004.md) | [(318.0%)](/filings/0001642380-26-000008.md) | [(1900.0%)](/filings/0001642380-26-000011.md) | [(4249.2%)](/filings/0001193125-25-274266.md) | [(2057.5%) d](/filings/0001642380-26-000004.md) | [(13790.6%)](/filings/0001642380-26-000008.md) | [(4770.7%)](/filings/0001642380-26-000011.md) |
| Net margin | % | [(11733.0%)](/filings/0001193125-25-274266.md) | [(2255.1%) d](/filings/0001642380-26-000004.md) | [(312.0%)](/filings/0001642380-26-000008.md) | [(1880.7%)](/filings/0001642380-26-000011.md) | [(4174.6%)](/filings/0001193125-25-274266.md) | [(2015.4%) d](/filings/0001642380-26-000004.md) | [(13406.3%)](/filings/0001642380-26-000008.md) | [(4711.3%)](/filings/0001642380-26-000011.md) |
| Diluted EPS | $ per share | [(0.98)](/filings/0001193125-25-274266.md) | not reported | [(0.26)](/filings/0001642380-26-000008.md) | [(0.30)](/filings/0001642380-26-000011.md) | [(0.34)](/filings/0001193125-25-274266.md) | not reported | [(0.12)](/filings/0001642380-26-000008.md) | [(0.31)](/filings/0001642380-26-000011.md) |
| Free cash flow | $m | [(5.6) d](/filings/0001193125-25-274266.md) | [(5.6) d](/filings/0001642380-26-000004.md) | [(6.1)](/filings/0001642380-26-000008.md) | [(6.5) d](/filings/0001642380-26-000011.md) | [(5.7) d](/filings/0001193125-25-274266.md) | [(7.0) d](/filings/0001642380-26-000004.md) | [(8.3)](/filings/0001642380-26-000008.md) | [(10.0) d](/filings/0001642380-26-000011.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [2.2](/filings/0001493152-23-012005.md) | [1.0](/filings/0001493152-24-014720.md) | [1.5](/filings/0000950170-25-043852.md) | [1.9](/filings/0001642380-26-000004.md) | [4.1](/filings/0001642380-26-000004.md) |
| Gross margin | % | [64.6%](/filings/0001493152-23-012005.md) | [(1.9%)](/filings/0001493152-24-014720.md) | [27.5%](/filings/0000950170-25-043852.md) | [39.3%](/filings/0001642380-26-000004.md) | [56.7%](/filings/0001642380-26-000004.md) |
| Operating margin | % | [(2444.3%)](/filings/0001493152-23-012005.md) | [(1878.6%)](/filings/0001493152-24-014720.md) | [(1672.4%)](/filings/0000950170-25-043852.md) | [(3245.1%)](/filings/0001642380-26-000004.md) | [(1260.8%)](/filings/0001642380-26-000004.md) |
| Net margin | % | [(2916.2%)](/filings/0001493152-23-012005.md) | [(7609.8%)](/filings/0001493152-24-014720.md) | [(1848.4%)](/filings/0000950170-25-043852.md) | [(3225.0%)](/filings/0001642380-26-000004.md) | [(1238.5%)](/filings/0001642380-26-000004.md) |
| Diluted EPS | $ per share | [(0.72)](/filings/0001493152-22-006677.md) | [(13.25)](/filings/0001493152-24-014720.md) | [(3.75)](/filings/0000950170-25-043852.md) | [(4.66)](/filings/0001642380-26-000004.md) | [(1.65)](/filings/0001642380-26-000004.md) |
| Free cash flow | $m | [(38.2)](/filings/0001493152-23-012005.md) | [(49.9)](/filings/0001493152-24-014720.md) | [(23.6)](/filings/0000950170-25-043852.md) | [(21.2)](/filings/0001642380-26-000004.md) | [(25.4)](/filings/0001642380-26-000004.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareBasicAndDiluted; Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/imdx/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BROADWOOD CAPITAL INC](/funds/1278387.md) | 2026-06-30 | $74.8m | 12,684,884 |  | Added +753,045 |
| [AWM Investment Company, Inc.](/funds/1535264.md) | 2026-06-30 | $16.7m | 2,836,692 |  | Added +30,436 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $4.3m | 735,847 |  | Added +198,686 |
| [PURA VIDA INVESTMENTS, LLC](/funds/1590144.md) | 2026-06-30 | $2.9m | 484,845 |  | Reduced −462,289 |
| [Family Office Research LLC](/funds/2041267.md) | 2026-06-30 | $2.2m | 368,849 |  | Added +241,583 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $1.5m | 256,903 |  | Reduced −5,150 |
| [JANE STREET GROUP, LLC](/funds/1595888.md) | 2026-06-30 | $930.3k | 157,682 |  | New +157,682 |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $888.1k | 150,521 |  | Added +15,176 |
| [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $735.0k | 124,576 |  | Reduced −8,015 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $543.5k | 92,124 |  | Added +41,370 |

## Recent filings

[All 670 filings](/companies/imdx/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-09-21 | 16:05 ET | [8-K](/filings/0001493152-26-043560.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001493152-26-043560 |
| 2026-08-10 | 16:14 ET | [10-Q](/filings/0001642380-26-000011.md) | Quarterly report, period 2026-06-30 | 0001642380-26-000011 |
| 2026-08-10 | 16:10 ET | [8-K](/filings/0001493152-26-036863.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-26-036863 |
| 2026-06-17 | 16:05 ET | [8-K](/filings/0001493152-26-029078.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001493152-26-029078 |
| 2026-05-13 | 16:15 ET | [10-Q](/filings/0001642380-26-000008.md) | Quarterly report, period 2026-03-31 | 0001642380-26-000008 |
| 2026-05-13 | 16:10 ET | [8-K](/filings/0001493152-26-022721.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001493152-26-022721 |
| 2026-05-13 | 16:05 ET | [8-K/A](/filings/0001493152-26-022708.md) | 8.01 Other events | 0001493152-26-022708 |
| 2026-04-30 | 16:14 ET | [DEF 14A](/filings/0001493152-26-020502.md) | Proxy statement, period 2026-04-30 | 0001493152-26-020502 |
| 2026-04-30 | 16:07 ET | [8-K](/filings/0001493152-26-020461.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-26-020461 |
| 2026-04-27 | 19:14 ET | [SCHEDULE 13D/A](/filings/0000919574-26-002415.md) | Ownership report, active investor, amended | 0000919574-26-002415 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001642380-26-000004.md), filed Mar 26, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/3a1a6eef-6fa5-42c2-a4e9-3b4051e5da4e)

## About the filer

- CIK: 1642380
- Tickers: IMDX
- Exchange: Nasdaq
- SIC code: 2835 In Vitro & In Vivo Diagnostic Substances
- State of incorporation: CA
- Filer category: Non-accelerated filer<br>Smaller reporting company

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:45 ET. No prices; not investment advice.